Payment overview · 2025
General Payments
$1,431.03
72 reported records · 16 companies
Healthcare provider profile · identity verified
Michael Alan Boyd, MD
Allopathic & Osteopathic Physicians|Family Medicine · FLEMINGSBURG, KY · NPI 1740270115
Verified facts
What the public records show
CMS Open Payments records show Michael Alan Boyd, MD received $1,431.03 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 387 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $313.29 | 21.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.51 | 13.9% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $196.23 | 13.7% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.33 | 8.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.70 | 7.5% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $97.86 | 6.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.77 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.24 | 3.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $47.96 | 3.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.68 | 3.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.66 | 3.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.03 | 3.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.21 | 2.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.70 | 1.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.61 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.25 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,431.03 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $246.31 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $216.48 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $183.60 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.01 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.19 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $106.70 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $97.86 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.77 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.32 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.05 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 156 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 205 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
156 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
83 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
387 | 37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1065 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1041 | 183 |
| Lisinopril | Lisinopril | 772 | 162 |
| Omeprazole | Omeprazole | 746 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 741 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 112 |
| Furosemide | Furosemide | 647 | 126 |
| Gabapentin | Gabapentin | 621 | 102 |
| Prednisone | Prednisone | 609 | 283 |
| Alprazolam | Alprazolam | 564 | 91 |
| Losartan Potassium | Losartan Potassium | 456 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 444 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 426 | 75 |
| Eliquis | Apixaban | 387 | 37 |
| Potassium Chloride | Potassium Chloride | 387 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 387 | 74 |
| Metformin Hcl | Metformin Hcl | 374 | 79 |
| Carvedilol | Carvedilol | 345 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 76 |
| Allopurinol | Allopurinol | 307 | 47 |
| Azithromycin | Azithromycin | 300 | 185 |
| Meloxicam | Meloxicam | 296 | 65 |
| Lorazepam | Lorazepam | 290 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 286 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 285 | 51 |
| Trazodone Hcl | Trazodone Hcl | 282 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 280 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 273 | 81 |
| Mirtazapine | Mirtazapine | 270 | 43 |
| Simvastatin | Simvastatin | 265 | 53 |
| Donepezil Hcl | Donepezil Hcl | 260 | 32 |
| Glipizide Er | Glipizide | 260 | 49 |
| Tramadol Hcl | Tramadol Hcl | 252 | 39 |
| Montelukast Sodium | Montelukast Sodium | 235 | 46 |
| Famotidine | Famotidine | 232 | 47 |
| Sertraline Hcl | Sertraline Hcl | 227 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 51 |
| Jardiance | Empagliflozin | 205 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 41 |
| Xarelto | Rivaroxaban | 180 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 179 | 71 |
| Fluoxetine Hcl | Fluoxetine Hcl | 176 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 175 | 104 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 168 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 157 | 23 |
| Ozempic | Semaglutide | 157 | 26 |
| Farxiga | Dapagliflozin Propanediol | 156 | 23 |
| Buspirone Hcl | Buspirone Hcl | 155 | 25 |
| Divalproex Sodium | Divalproex Sodium | 151 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 144 | 97 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 143 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 143 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 28 |
| Memantine Hcl | Memantine Hcl | 139 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 130 | 27 |
| Cephalexin | Cephalexin | 128 | 69 |
| Spironolactone | Spironolactone | 128 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 124 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 120 | 30 |
| Amoxicillin | Amoxicillin | 117 | 67 |
| Fluconazole | Fluconazole | 117 | 53 |
| Nystatin | Nystatin | 117 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 115 | 19 |
| Metformin Hcl Er | Metformin Hcl | 113 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 19 |
| Baclofen | Baclofen | 102 | 15 |
| Estradiol | Estradiol | 101 | 19 |
| Finasteride | Finasteride | 101 | 18 |
| Cefdinir | Cefdinir | 94 | 54 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | suppressed |
| Constulose | Lactulose | 90 | suppressed |
| Entresto | Sacubitril/Valsartan | 89 | suppressed |
| Sucralfate | Sucralfate | 89 | 25 |
| Ezetimibe | Ezetimibe | 87 | 17 |
| Myrbetriq | Mirabegron | 87 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 86 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 85 | 12 |
| Januvia | Sitagliptin Phosphate | 84 | 19 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 83 | suppressed |
| Ibuprofen | Ibuprofen | 81 | 22 |
| Clonazepam | Clonazepam | 78 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | 11 |
| Glipizide | Glipizide | 77 | 13 |
| Atenolol | Atenolol | 75 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 14 |
| Pregabalin | Pregabalin | 75 | 11 |
| Primidone | Primidone | 75 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 74 | 29 |
| Risperidone | Risperidone | 74 | suppressed |
| Mupirocin | Mupirocin | 72 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 49 |
| Levetiracetam | Levetiracetam | 64 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 14 |
| Diazepam | Diazepam | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 59 | suppressed |
| Ondansetron Odt | Ondansetron | 57 | suppressed |
| Rivastigmine | Rivastigmine | 57 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 12 |
| Glimepiride | Glimepiride | 56 | 12 |
| Lactulose | Lactulose | 56 | 24 |
| Promethazine Hcl | Promethazine Hcl | 56 | suppressed |
| Metolazone | Metolazone | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Lansoprazole | Lansoprazole | 54 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | suppressed |
| Rexulti | Brexpiprazole | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 50 | 14 |
| Benazepril Hcl | Benazepril Hcl | 49 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Gemtesa | Vibegron | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | suppressed |
| Colchicine | Colchicine | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 27 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Haloperidol | Haloperidol | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 36 | 36 |
| Nitroglycerin | Nitroglycerin | 35 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 20 |
| Clonidine | Clonidine | 30 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Motegrity | Prucalopride Succinate | 29 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 29 | suppressed |
| Nyamyc | Nystatin | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Corlanor | Ivabradine Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Tresiba | Insulin Degludec | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Dipyridamole | Dipyridamole | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 14 |
| Pindolol | Pindolol | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Erythromycin Ethylsuccinate | Erythromycin Ethylsuccinate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Tolvaptan | Tolvaptan | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,431.03 · 72 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error